# OnCo record paper-rummel-lancet (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rummel-lancet/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rummel-lancet" ;
  schema:name "Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial"@en ;
  schema:description "Paper cited by one treatment page, indexed on Europe PMC as PubMed record 23433739 and published in The Lancet; the citing page links this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-rummel-lancet/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(12)61763-2>, <https://pubmed.ncbi.nlm.nih.gov/23433739/>, <https://europepmc.org/article/MED/23433739> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(12)61763-2> ;
  schema:datePublished "2013"^^xsd:gYear ;
  schema:author "Rummel MJ, Niederle N, Maschmeyer G, et al." ;
  onco:related <https://onco.cc/drugs/bendamustine/> ;
  onco:journals <https://onco.cc/journals/lancet/> .